Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 20 November 2025 - 23 November 2025

Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) heads into Sunday, November 23, 2025, with its first commercial fibromyalgia drug now on pharmacy shelves, a beefed‑up share repurchase program, and a sharply expanded at‑the‑market (ATM) equity facility. Together, those moves are redefining the risk‑reward profile of this small‑cap biotech just as investors focus on how quickly new product Tonmya can ramp. Tonix…
23 November 2025
····
Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Published: November 23, 2025 Pfizer Inc. (NYSE: PFE) heads into the new week with its share price stuck around the mid‑$20s, a near‑7% dividend yield, and a flurry of fresh headlines that could shape the stock’s next move. Over the past few days the pharma giant has closed a multibillion‑dollar obesity acquisition, secured a major new U.S. cancer approval, sold…
23 November 2025
····
Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer stock heads into the weekend trading just above $25, with investors digesting a busy week of news: a strong Q3 earnings beat, a fresh FDA cancer-drug approval, completion of a multi‑billion‑dollar obesity deal, a new $6 billion bond issue – and even a headline‑grabbing bird flu case that once again reminds markets of Pfizer’s role in vaccines and antivirals.…
23 November 2025
····
Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck & Co., Inc. (NYSE: MRK) is firmly in the spotlight this weekend as the U.S. pharma giant juggles shareholder protection, a higher dividend, and fresh regulatory wins — all while its share price trades near the upper end of its 12‑month range. Note: This article refers to Merck & Co., Inc., the U.S. company based in Rahway, New Jersey…
22 November 2025
····
Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk stock is back in the spotlight today, 21 November 2025, as a cluster of breaking headlines hits the world’s most closely watched weight‑loss drug maker. As of late morning in New York, Novo Nordisk’s U.S. ADR (NYSE: NVO) is trading around $47.07, down roughly 1.1% on the day, giving the company a market value close to $213 billion.…
21 November 2025
····
Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer’s share price is back in the spotlight on Friday, November 21, 2025, as investors digest strong Phase 3 flu-vaccine data, a $6 billion bond sale to fund its obesity-drug deal, and ongoing debate around the company’s roughly 7% dividend yield. Pfizer stock price on November 21, 2025 Pfizer (NYSE: PFE) staged a solid rebound in Friday’s regular session: For…
21 November 2025
····
Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (NASDAQ: TELO) shares react to new preclinical leukemia data and a director resignation on November 21, 2025. Here’s what today’s Telomir-1 news means for TELO stock and investors. What happened to Telomir Pharmaceuticals (TELO) today? On Friday, November 21, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a Miami‑based preclinical biotech focused on small‑molecule therapies for cancer, aging and age‑related…
21 November 2025
··
Pfizer Stock Today, November 20, 2025: Price Slide, Dividend Debate, Flu Shot Win and Texas Settlement

Pfizer Stock Today, November 20, 2025: Price Slide, Dividend Debate, Flu Shot Win and Texas Settlement

Pfizer stock (NYSE: PFE) spent most of Thursday in the red as investors weighed a near‑7% dividend yield against fresh legal headlines, new R&D wins and ongoing questions about the company’s post‑COVID growth story. As of late U.S. trading on November 20, 2025, Pfizer shares were changing hands around $24.45, down roughly 1.7% on the day, with heavy volume of…
20 November 2025
···
Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) secured a $1.5 billion Ares loan, outlined a three‑year strategy targeting up to 10% revenue growth in 2026, and confirmed a $140 million U.S. manufacturing expansion as it races toward cash breakeven by 2028. Moderna’s pivotal day: liquidity boost, strategy reset and manufacturing push Moderna, Inc., the mRNA‑vaccine pioneer behind Spikevax®, is back in the spotlight today after…
20 November 2025
····
Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed”) is back in the spotlight today after announcing a “major breakthrough” in its ibogaine supply chain and emerging as one of the more active healthcare micro‑caps in pre‑market trading. The Nasdaq‑listed psychedelic biotech disclosed that it has secured a sustainable, pharmaceutical‑grade ibogaine supply through its strategic partner PsyLabs, including an initial shipment of…
20 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (November 20, 2025): Wegovy Price Cuts, Alzheimer’s ‘Lottery Ticket’ Trials and Denmark GDP Put NVO Back in the Spotlight

Novo Nordisk stock is back on traders’ screens today as a cluster of fresh headlines – from high‑stakes Alzheimer’s trials to aggressive Wegovy price cuts and new Danish GDP data – reshapes the narrative around the Ozempic maker. On Thursday, November 20, 2025, Novo Nordisk’s U.S.-listed ADR (ticker NVO) is trading around $49, roughly in line with Wednesday’s close, after…
20 November 2025
····
RANI Stock Today (Nov 19, 2025): Rani Therapeutics slips to $1.75 as traders weigh October’s Chugai deal and year‑end catalysts

RANI Stock Today (Nov 19, 2025): Rani Therapeutics slips to $1.75 as traders weigh October’s Chugai deal and year‑end catalysts

Updated: November 19, 2025 Rani Therapeutics Holdings (NASDAQ: RANI) finished Wednesday, Nov. 19, 2025 at $1.75, down from $1.86 on Tuesday. The stock opened at $1.83, traded between $1.70–$1.90, and moved ~2.5M shares on the day, according to end‑of‑day pricing data. Yahoo Finance Today’s trading at a glance (19.11.2025) Was there fresh company news today?As of publication on Nov. 19,…
20 November 2025
···
1 … 34 35 36 37 38 … 46

Stock Market Today

  • Dollar Falls Amid Stock Rally and Stronger US Economic Data
    January 22, 2026, 12:48 PM EST. The US dollar index fell 0.28% as strong stock gains reduced demand for the currency. US economic data partly contained dollar losses: initial jobless claims rose by 1,000 to 200,000, below expectations; Q3 GDP was revised up to 4.4%; and November personal spending matched forecasts. The Fed's preferred inflation gauge, the core PCE price index, increased 0.2% month-over-month. President Trump signaled no tariffs on European goods opposing Greenland acquisition plans, supporting the euro, which rose 0.34%. Market expectations show only a 5% chance of a Fed rate cut at January's meeting, with greater cuts anticipated in 2026 amid Fed liquidity increases. The yen weakened to a one-week low on a Nikkei rally dampening safe-haven demand. The dollar remains pressured by speculation of a dovish Fed Chair appointment.
Go toTop